Helen S. Kim has served on Aktis Oncology's board of directors since February 2021. She is a Senior Managing Director of Vida Ventures and was previously a Partner at The Column Group and Executive Vice President of Business Development at Kite Pharma, where she led the corporate development that resulted in its acquisition by Gilead. She currently serves on the boards of Prothena and several private biotechnology companies, and received a BS in Chemical Engineering from Northwestern University and an MBA from the University of Chicago.